论文部分内容阅读
目的评价希罗达联合顺铂治疗晚期胃癌的近期疗效。方法希罗达2500mg/(m2.d),分早晚2次饭后30min口服,连服14d。顺铂20mg/次,静脉滴注,第1～5天(或40mg/次,静脉滴注,第1～3天),每21天为1个周期,连用2～3个周期为一个疗程。结果34例可评价疗效,部分缓解(PR)16例,总有效为47.1%,毒副反应主要是骨髓抑制和消化道反应。结论希罗达联合顺铂治疗晚期胃癌可获较高疗效,毒副反应轻,值得推广应用。
Objective To evaluate the short-term effect of Xeloda combined with cisplatin in the treatment of advanced gastric cancer. Methods Xeloda 2500mg / (m2.d), points in the morning and evening 2 times 30min after oral administration, and even served 14d. Cisplatin 20mg / time, intravenous drip, the first 1 to 5 days (or 40mg / intravenous drip, 1 to 3 days), every 21 days for a cycle, once every 2 to 3 cycles for a course of treatment. Results The curative effect was evaluated in 34 cases, with partial remission (PR) in 16 cases and the total effective rate was 47.1%. Toxic and adverse reactions were mainly bone marrow suppression and digestive tract reaction. Conclusion Xeloda combined with cisplatin in the treatment of advanced gastric cancer can be a higher efficacy, toxicity, it is worth promoting the application.